BioCryst Pharmaceuticals | BCRX - Gross Profit On Sales


BioCryst Pharmaceuticals reported $153.05M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Chugai Pharma JPY 258.74B 25.81B Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novavax USD 125.04M 76.09M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026